As summarized in Supplementary Figure 3, these data collectively demonstrate that combined administration of IL-2/JES6-1 immunocomplexes and anti-IL-5 mAb, which allows for Foxp3+ Treg expansion in the absence of eosinophilia, is highly effective at ameliorating DSS-induced colitis compared to the use of IL-2/JES6-1 immunocomplexes or anti-IL-5 mAb alone. The gene discussed is IL5; the disease is colitis.